FSD Pharma Receives First Delivery of Canntab Equipment with a Capacity to Manufacture Approx. 1,500,000 Tablets per Day

canntab, c.pill, cannabis
info

FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FSE: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that the Company has received its first delivery of manufacturing equipment at its Cobourg plant from Canntab Therapeutics Limited (CSE: PILL) (“Canntab“), a leader in the rapidly growing cannabis pill market. The manufacturing equipment consists of a fully GMP High output Tablet press capable of pressing more than 1,500,000 tablets per day, as well as blending machinery, large scale process and drying equipment and packaging equipment. read more

Advantage achieves key milestone with filing of Preliminary Economic Assessment (PEA) report and confirms Cauchari project development on track

V.AAL, Advantage Lithium, lithium, Argentina, David Sidoo

Advantage Lithium Corp. (the “Corporation” or “Advantage Lithium”) (TSX Venture: AAL) (OTCQX: AVLIF) is pleased to announce the filing on SEDAR of its Preliminary Economic Assessment (“PEA”) Report following summary results announced on August 14, 2018. read more

FSD Pharma Receives First Delivery of Cantabb Equipment with a Capacity to Manufacture Approx. 1,500,000 Tablets Per Day

C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that the Company has received its first delivery of manufacturing equipment at its Cobourg plant from Canntab  Therapeutics Limited (CSE:PILL) (“Canntab“), a leader in the rapidly growing cannabis pill market. The manufacturing equipment consists of a fully GMP High output Tablet press capable of pressing more than 1,500,000 tablets per day, as well as blending machinery, large scale process and drying equipment and packaging equipment. read more

Aben Intersects Additional, Shallow High-Grade Gold Mineralization at the North Boundary Zone of the Forrest Kerr Project in BC’s Golden Triangle

Aben Resources Ltd. (TSX-V: ABN) (OTCQB: ABNAF) (Frankfurt: E2L2) (the “Company”) announces that additional analytical results have been received from the early-stage drilling at the 23,000 hectare Forrest Kerr Property (the “Property”) located in the Golden Triangle region of British Columbia. The eight drill holes reported here consist of step-out drilling at the North Boundary Zone and most of the holes intersected shallow, high-grade gold mineralization. Highlights include: 5.08 g/t Au over 12.0m in hole FK18-12; 23.3 g/t Au over 2.0m in hole FK18-13; and 10.62 g/t Au over 3.0m in hole FK18-17. To date, final analytical results have been received for 3,000m of a total projected 10,000m (table of values and hole descriptions near end of release). read more

Bayhorse Silver Maiden Resource 6 Million Ounce, NI-43-101 Inferred, Bayhorse Silver Mine, Oregon, USA.

V.BHS, Bayhorse Silver, silver, Oregon

Bayhorse Silver Inc. (TSXV: BHS) (The “Company” or “Bayhorse”) is pleased to announce the release of a Maiden Inferred Mineral Resource for the 100% controlled Bayhorse Silver Mine, Oregon, USA. The maiden resource is comprised of 292,300 short tons at an average grade of 21.65 troy ounces per ton (opt) silver (Ag) for total contained silver of 6,328,400 ounces. The mineralized material contains significant amounts of copper (Cu) and zinc (Zn), however the historic data utilized in the mineral resource estimate did not allow for a reliable calculation of the grade of Cu and Zn. read more

FSD Pharma and SciCann Therapeutics Launch Cardiovascular Research Program in Tel Aviv University

C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (“FSD Pharma” or “FSD“) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce the launch of a comprehensive sponsored research program in Tel Aviv University together with its strategic R&D partner, SciCann Therapeutics Inc. (“SciCann“), focused on the cardiovascular disease field. The new research program is aimed at the development of novel and proprietary cannabinoid-based treatments for the prevention and treatment of atherosclerosis, the underlying factor for most cases of stroke and cardiac stenosis events in the western world. read more

Advantage Lithium: Proving up a Lithium Resource in Argentina

V.ALL, Advantage Lithium, lithium, Argentina

Argentina has been in the news. 60% interest rates, a recession and a temporary 8% export tax are not good news for miners. However, at this point, David Sidoo, CEO of Advantage Lithium (V.AAL) is cautiously optimistic. “It’s effecting all the juniors working in Argentina,” said Sidoo. “it surprised the market and it is going to be painful for the next twelve months. However, we have built a contingency into our Preliminary Economic Assessment. But it is important to explain to investors.” read more

Canntab Sets New All-Time High Trading Prices and Volume

canntab, c.pill, cannabis
info

Canntab Therapeutics Limited (CSE: PILL) (“Canntab” or the “Company“), a leader in the development of the cannabis in tablet or capsule form, is pleased to announce that the Company’s common shares (“Common Shares“) yesterday reached new all-time daily high and closing prices of $1.74 and $1.41, respectively, on the Canadian Securities Exchange (the “CSE“). These numbers exceed the Company’s previous all-time highs by 39.2% and 15.6%, which were also set earlier this week. In addition, the Company traded an aggregate of 1,583,326 Common Shares yesterday at a total dollar value of $2.06M, which constitutes its all-time high daily volume and exceeds the Company’s previous highs, set on the Company’s opening day of trading on April 20, 2018. read more